Novacyt

Novacyt Debt/Market Cap

The Debt to Market Capitalization Ratio of Novacyt (ALNOV.PA) as of Oct 18, 2026 is 41.67 %. In the previous year, Debt to Market Capitalization Ratio was 47.40 % — a change of -12.10% (lower).

Debt/Market Cap

41.67 %

YoY

-12.10%

Last updated:

Debt to Market Capitalization Ratio of Novacyt is 2025 41.67 % . Debt to Market Capitalization Ratio of Novacyt was 2024 47.40 % . It decreases by -12.10% lower compared to the previous year.

The Novacyt Debt/Market Cap history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/Market Cap
Date
Debt/Market Cap
Jan 1, 2018
17.65 GBP
Jan 1, 2019
34.03 GBP
Jan 1, 2020
11.07 GBP
Jan 1, 2021
7.46 GBP
Jan 1, 2022
3.48 GBP
Jan 1, 2023
54.69 GBP
Jan 1, 2024
47.40 GBP
Jan 1, 2025
41.67 GBP
The Novacyt Debt/Market Cap history
YEARDebt/Market CapYoY
41.67 %-12.10%
47.40 %-13.32%
54.69 %+1,471.56%
3.48 %-53.37%
7.46 %-32.57%
11.07 %-67.48%
34.03 %+92.80%
17.65 %+51.43%
11.66 %-35.46%
18.06 %+58.95%
11.36 %+228.02%
3.46 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Novacyt Stock analysis

What does Novacyt do? Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Novacyt stock

Debt to Market Capitalization Ratio of Novacyt is 41.67 % in 2025.

Debt to Market Capitalization Ratio of Novacyt changed from 47.40 % to 41.67 %, representing a -12.10% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt to Market Capitalization Ratio Novacyt since 2006 – with annual values, charts, and detailed analysis.

Debt/Market Cap compares total debt to the market value of equity. It provides a market-based view of financial leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt to Market Capitalization Ratio's Novacyt with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Novacyt

All Key Metrics — Novacyt